Development of a clinical scoring system for assessment of immunosuppression in patients with tuberculosis and HIV infection without access to CD4 cell testing – results from a cross-sectional study in Ethiopia

References

• WHO. Global tuberculosis report 2012 . 2012; Geneva: World Health Organization.
   Google Scholar
• Lawn SD, Wood R. Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries. Clin Infect Dis. 2005; 41: 1783–6.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, etal. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010; 362: 697–706.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, etal. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011; 365: 1482–91.
   PubMed Web of Science ®Google Scholar
• Blanc F-X, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, etal. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011; 365: 1471–81.
   PubMed Web of Science ®Google Scholar
• WHO. WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013; Geneva: World Health Orgainzation.
   Google Scholar
• Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, Suwanvattana P, etal. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr. 2012; 60: 377–83.
   PubMed Web of Science ®Google Scholar
• Laureillard D, Marcy O, Madec Y, Chea S, Chan S, Borand L, etal. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS. 2013; 27: 2577–86.
   PubMed Web of Science ®Google Scholar
• French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004; 18: 1615–27.
   PubMed Web of Science ®Google Scholar
• Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005; 5: 361–73.
   PubMed Web of Science ®Google Scholar
• Török ME, Yen NTB, Chau TTH, Mai NTH, Phu NH, Mai PP, etal. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV) – associated tuberculous meningitis. Clin Infect Dis. 2011; 52: 1374–83.
   PubMed Web of Science ®Google Scholar
• Kagaayi J, Makumbi F, Nakigozi G, Wawer MJ, Gray RH, Serwadda D, etal. WHO HIV clinical staging or CD4 cell counts for antiretroviral therapy eligibility assessment? An evaluation in rural Rakai district, Uganda. AIDS. 2007; 21: 1208–10.
   PubMed Web of Science ®Google Scholar
• Medina LA, Kigozi J, Amurwon J, Muchabaiwa L, Nyanzi Wakaholi B, Mujica Mota RE, etal. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PLoS One. 2012; 7: e33672.
   PubMed Web of Science ®Google Scholar
• Federal Ministry of Health. Tuberculosis, leprosy and TB/HIV prevention and control programme . 2008; Ethiopia: Addis Ababa.
   Google Scholar
• Federal Ministry of Health. Guidelines for HIV counselling and testing in Ethiopia . 2007; Ethiopia: Addis Ababa.
   Google Scholar
• Federal Ministry of Health. Guidelines for implementation of the antiretroviral therapy programme in Ethiopia . 2007; Ethiopia: Addis Ababa.
   Google Scholar
• Jaffar S, Grant AD, Whitworth J, Smith PG, Whittle H. The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull World Health Organ. 2004; 82: 462–9.
   PubMed Web of Science ®Google Scholar
• Teck R, Ascurra O, Gomani P, Manzi M, Pasulani O, Kusamale J, etal. WHO clinical staging of HIV infection and disease, tuberculosis and eligibility for antiretroviral treatment: relationship to CD4 lymphocyte counts. Int J Tuberc Lung Dis. 2005; 9: 258–62.
   PubMed Web of Science ®Google Scholar
• Baveewo S, Ssali F, Karamagi C, Kalyango JN, Hahn JA, Ekoru K, etal. Validation of World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral therapy and clinical predictors of low CD4 cell count in Uganda. PLoS One. 2011; 6: e19089.
   PubMed Web of Science ®Google Scholar
• Wells PS, Ginsberg JS, Anderson DR, Kearon C, Gent M, Turpie AG, etal. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med. 1998; 129: 997–1005.
   PubMed Web of Science ®Google Scholar
• Dolgin M, TCC of the NYHA. Nomenclature and criteria for diagnosis for diseases of the heart and great vessels . 1994; Boston: Little Brown. 9th ed.
   Google Scholar
• Lynen L, An S, Koole O, Thai S, Ros S, De Munter P, etal. An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia. J Acquir Immune Defic Syndr. 2009; 52: 40–8.
   PubMed Web of Science ®Google Scholar
• Nzou C, Kambarami RA, Onyango FE, Ndhlovu CE, Chikwasha V. Clinical predictors of low CD4 count among HIV infected pulmonary tuberculosis clients: a health facility-based survey. South African Med J. 2010; 100: 602–5.
   PubMed Web of Science ®Google Scholar
• Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, etal. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med. 2010; 362: 707–16.
   PubMed Web of Science ®Google Scholar
• Soto A, Solari L, Agapito J, Acuna-Villaorduna C, Lambert M-L, Gotuzzo E, etal. Development of a clinical scoring system for the diagnosis of smear-negative pulmonary tuberculosis. Braz J Infect Dis. 2008; 12: 128–32.
   PubMed Web of Science ®Google Scholar
• Stiell IG, Clement CM, Brison RJ, Rowe BH, Borgundvaag B, Aaron SD, etal. A risk scoring system to identify emergency department patients with heart failure at high risk for serious adverse events. Acad Emerg Med. 2013; 20: 17–26.
   PubMed Web of Science ®Google Scholar
• Chumbler NR, Williams LS, Wells CK, Lo AC, Nadeau S, Peixoto AJ, etal. Derivation and validation of a clinical system for predicting pneumonia in acute stroke. Neuroepidemiology. 2010; 34: 193–9.
   PubMed Web of Science ®Google Scholar
• Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: 1837–47.
   PubMed Web of Science ®Google Scholar
• Wainer H. Estimating coefficients in linear models: it don't make no nevermind. Psycological Bull. 1976; 83: 213–17.
   Web of Science ®Google Scholar
• Perloff JM, Persons JB. Biases resulting from the use of indexes: an application to attributional style and depression. Psychological Bull. 1988; 103: 95–104.
   PubMed Web of Science ®Google Scholar
• Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use . 2008; New York, USA: Oxford University Press.
   Google Scholar
• Gustafson P, Gomes VF, Vieira CS, Samb B, Nauclér A, Aaby P, etal. Clinical predictors for death in HIV-positive and HIV-negative tuberculosis patients in Guinea-Bissau. Infection. 2007; 35: 69–80.
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis. 2010; 10: 67.
   PubMed Web of Science ®Google Scholar
• WHO. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders . 2012; Geneva: World Health Organization.
   Google Scholar
• Malaza A, Mossong J, Bärnighausen T, Viljoen J, Newell M-L. Population-based CD4 counts in a rural area in South Africa with high HIV prevalence and high antiretroviral treatment coverage. PLoS One. 2013; 8: e70126.
   PubMed Web of Science ®Google Scholar